Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma-Reference-Cited by-同舟云学术

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

Published:2016-08-01 Issue:36 Volume:7 Page:58142-58147
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Gaudio Eugenio¹,Tarantelli Chiara¹,Ponzoni Maurilio²,Odore Elodie³,Rezai Keyvan³,Bernasconi Elena¹,Cascione Luciano¹⁴,Rinaldi Andrea¹,Stathis Anastasios⁴,Riveiro Eugenia⁵,Cvitkovic Esteban⁵,Zucca Emanuele⁴,Bertoni Francesco¹⁴

Affiliation:

1. Lymphoma and Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona, Switzerland

2. San Raffaele Scientific Institute, Milan, Italy

3. Institut Curie, Hôpital René Huguenin, Saint-Cloud, France

4. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland

5. Oncology Therapeutic Development, Clichy, France

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular hybridization: a powerful tool for multitarget drug discovery;Expert Opinion on Drug Discovery;2024-03-08

2. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models;International Journal of Molecular Sciences;2024-01-19

3. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

4. Physachenolide C is a Potent, Selective BET Inhibitor;Journal of Medicinal Chemistry;2022-12-28

5. Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer;Current Medicinal Chemistry;2021-04-20